PDGFRB and atrial fibrillation: Here we show that combinations of the mTOR pathway inhibitor vistusertib with either the PDGFR inhibitor cediranib or the SRC family inhibitor saracatinib are synergistic at doses that are more efficacious than cisplatin/pemetrexed across our various MPM/AF cocultures (Fig. 6B, C).